Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Peptic Ulcers Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Peptic Ulcers Overview | 8 | 1 |
| Peptic Ulcers Therapeutics under Development by Companies | 9 | 1 |
| Peptic Ulcers Pipeline Products Glance | 10 | 2 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Peptic Ulcers Products under Development by Companies | 12 | 1 |
| Peptic Ulcers Companies Involved in Therapeutics Development | 13 | 10 |
| Ache Laboratorios Farmaceuticos S/A | 13 | 1 |
| Astellas Pharma Inc. | 14 | 1 |
| ChoDang Pharm Co., Ltd. | 15 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 16 | 1 |
| Kukje Pharmaceutical Industry Co., Ltd. | 17 | 1 |
| RaQualia Pharma Inc. | 18 | 1 |
| Sequella, Inc. | 19 | 1 |
| Sihuan Pharmaceutical Holdings Group Ltd. | 20 | 1 |
| Sinil Pharmaceutical Co., Ltd | 21 | 1 |
| Yooyoung Pharmaceutical Co., Ltd. | 22 | 1 |
| Peptic Ulcers Therapeutics Assessment | 23 | 8 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Combination Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 1 |
| Assessment by Molecule Type | 30 | 1 |
| Drug Profiles | 31 | 17 |
| (ecabet + ranitidine) Drug Profile | 31 | 1 |
| (lansoprazole + omeprazole) Drug Profile | 32 | 1 |
| anaprazole sodium Drug Profile | 33 | 1 |
| ASP-6537 Drug Profile | 34 | 1 |
| DWJ-206 Drug Profile | 35 | 1 |
| KJ-14001 Drug Profile | 36 | 1 |
| PDI-39 Drug Profile | 37 | 1 |
| PMKS-005 Drug Profile | 38 | 1 |
| RQ-00000774 Drug Profile | 39 | 1 |
| SI-001002 SR Drug Profile | 40 | 1 |
| Small Molecule to Inhibit Proton Pump for Peptic Ulcers Drug Profile | 41 | 1 |
| Small Molecules for Gastric Ulcers Drug Profile | 42 | 1 |
| SQ-109 Drug Profile | 43 | 4 |
| YYD-601 Drug Profile | 47 | 1 |
| Peptic Ulcers Dormant Projects | 48 | 2 |
| Peptic Ulcers Discontinued Products | 50 | 1 |
| Peptic Ulcers Product Development Milestones | 51 | 5 |
| Featured News &Press Releases | 51 | 1 |
| Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies | 51 | 1 |
| Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers | 52 | 1 |
| Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck | 52 | 1 |
| Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations | 53 | 1 |
| Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy | 53 | 1 |
| Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) | 54 | 1 |
| Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) | 54 | 1 |
| Jun 01, 2007: AstraZeneca s Prilosec Patents Upheld By Court | 55 | 1 |
| Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court | 55 | 1 |
| Appendix | 56 | 2 |
| Methodology | 56 | 1 |
| Coverage | 56 | 1 |
| Secondary Research | 56 | 1 |
| Primary Research | 56 | 1 |
| Expert Panel Validation | 56 | 1 |
| Contact Us | 56 | 1 |
| Disclaimer | 57 | 1 |